Chromatography
From Discovery to Production of Active Biotherapeutic and Pharmaceutical Ingredients
Jun 19 2018
Kromasil fits across the entire biotherapeutic and pharmaceutical organisations. Typically, researchers carry out method development using Kromasil UHPLC and HPLC columns based on 1.8 - 5 μm particle sizes. Then scientists and engineers in discovery, process and manufacturing departments scale the method up according to their needs using the same Kromasil stationary phases in prepacked columns and bulk ranging from 7 to 25 μm. This Kromasil capability to supply the entire development and production path of an API is unique in the market and shortens the timeline plus minimises costs when producing a drug. With 30 years of experience, Kromasil continues to expand its list of products, provides ready-made columns as well as bulk material for normal phase, reversed phase, chiral, HILIC, SFC and SMB chromatography.
For more information go to www.kromasil.com.
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Apr 22 2024 Marrakech, Morroco
Making Pharmaceuticals Exhibition & Conference
Apr 23 2024 Coventry, UK
Apr 23 2024 Kintex, South Korea
Apr 23 2024 Seoul, South Korea
Apr 24 2024 Jakarta, Indonesia